Alongside Intercept, Genfit is the leader in the NASH fibrosis race - it is currently conducting a Phase 3 trial evaluating its lead drug candidate elafibranor (readout expected in 2019).

We propose a method for selling options that defies many myths around options selling. We analyzed options prices using statistical modelling and calculus to improve the "expected value" of trading ...

Whether you’re a novice bettor or a seasoned veteran, you’ve almost certainly heard of positive expected value betting. After all, there are betting influencers and podcast hosts who talk about the ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. What if I say that starting a business is unnatural? The venture is always risky, and we’re ...

Tasked with driving innovation and improving quality while simultaneously controlling costs, healthcare leaders are in an incredibly difficult position. As healthcare costs continue to rise, these ...